Management of Advanced Prostatic Cancer

Parmar, H.; Charlton, Christopher; Lightman, Stafford L.

doi:10.1016/s0140-6736(89)91948-x

Cited by 3 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most patients with advanced prostatic cancer respond to androgen deprivation for a variable period which may last for several years [1][2][3].…”

Section: Discussionmentioning

confidence: 99%

“…Surgical or medical (LHRH agonist) castration may induce remission in the majority of patients [1][2]. Those who have progressive disease remain a therapeutic challenge [3] since most patients eventually die of their disease [4]. Study of animal prostate tumour models suggest that growth factors in addition to testosterone may be of importance in modulating tumour growth [5,6].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic response to somatostatin analogue, BIM 23014, in metastatic prostatic cancer

et al. 1992

Self Cite

View full text Add to dashboard Cite

Metastatic prostate cancer is well known to respond to hormonal manipulations, but once progression occurs new treatment modalities are required. Specific and systemic antitumour therapy is preferable to local treatments such as radiotherapy in such patients. The finding that somatostatin analogue, BIM 23014, inhibits prostatic tumour growth in animal models is of great interest. We treated 25 poor risk patients with progressive metastatic prostate cancer. Sixteen had also failed to respond to 'total androgen blockade'. Two patients have achieved a partial remission, one of which is maintained at over 30 months, and three had stable disease for over 6 months. Side effects have consisted of mild diarrhoea and abdominal cramp in the first few days of treatment in a minority of the patients. These results are encouraging and further randomized studies are in progress.

show abstract

“…Most patients with advanced prostatic cancer respond to androgen deprivation for a variable period which may last for several years [1][2][3].…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Therapeutic response to somatostatin analogue, BIM 23014, in metastatic prostatic cancer

et al. 1992

Self Cite

View full text Add to dashboard Cite

show abstract

“…The patients were then stratified into risk groups according to low-risk, intermediate-risk or high-risk subgroups (see Supplementary Table 1 [1, [16][17][18]). All patients who entered the model were therefore successfully treated as true positives in risk of a recurrence of NMIBC or progression to MIBC.…”

Section: • • Patient Populationmentioning

confidence: 99%